Taro Pharmaceutical Industries Ltd. (NYSE:TARO) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Thursday.

Separately, TheStreet downgraded shares of Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a report on Wednesday, August 9th.

Taro Pharmaceutical Industries (TARO) opened at 112.69 on Thursday. Taro Pharmaceutical Industries has a 12-month low of $92.28 and a 12-month high of $124.52. The stock has a 50 day moving average price of $104.93 and a 200 day moving average price of $111.57. The stock has a market cap of $4.56 billion, a P/E ratio of 11.48 and a beta of 0.65.

WARNING: This news story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/30/taro-pharmaceutical-industries-ltd-taro-rating-increased-to-buy-at-bidaskclub.html.

Large investors have recently made changes to their positions in the stock. River Road Asset Management LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 33.3% in the 2nd quarter. River Road Asset Management LLC now owns 65,470 shares of the company’s stock valued at $7,337,000 after acquiring an additional 16,350 shares during the last quarter. Creative Planning lifted its holdings in shares of Taro Pharmaceutical Industries by 3.8% in the 2nd quarter. Creative Planning now owns 7,186 shares of the company’s stock valued at $805,000 after acquiring an additional 265 shares during the last quarter. Anchor Capital Advisors LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 0.4% in the 2nd quarter. Anchor Capital Advisors LLC now owns 20,733 shares of the company’s stock valued at $2,323,000 after acquiring an additional 77 shares during the last quarter. Aperio Group LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 46.9% in the 2nd quarter. Aperio Group LLC now owns 50,826 shares of the company’s stock valued at $5,696,000 after acquiring an additional 16,233 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 19.0% in the 2nd quarter. Acadian Asset Management LLC now owns 42,799 shares of the company’s stock valued at $4,796,000 after acquiring an additional 6,824 shares during the last quarter. 14.20% of the stock is owned by hedge funds and other institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Receive News & Stock Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.